Driving the Next Generation of Oncology Diagnostics & Therapeutics:
We Cannot Do It Alone

Thursday 28th of April, 2022 | 6.00pm - 8.00pm | London, UK | In-Person Event Only

Welcome to this exclusive event providing senior leaders in pharma and biotechs with an opportunity to hear from innovative start-ups and fellow biopharma companies on how they are actioning genomics to achieve long-term strategic stability and clinical success in oncology therapeutic development.

This is your chance to discover the latest biomarker and CDx strategies to guarantee broader patient adoption of oncology therapeutics and how Illumina is working to bridge the different ecosystems across the cancer care continuum, from early innovation to patient care, to improve the cancer patient journey.

Join this Engager to connect and network over appetizers and drinks with Directors, Heads & C-Level Executives within the translational medicine and clinical development arena. Share your goal of improving health outcomes in oncology and support one another in developing the next generation of oncology therapeutics.

EXPERT SPEAKERS:

Bobby Kaura

Director, Illumina for Start-Ups, Global Ecosystem Development

Illumina

Flora Berisha

Head of Dx Strategic Partnering, Oncology

Janssen, Global R&D

Jason Yip

Co-Founder

Tailor Bio

Megan Townsend

Business Development Manager, CDx Partnerships

Illumina

VENUE

Savage Garden Rooftop Bar

Floor 12, 7 Pepys St, London EC3N 4AF

Check Out Their Website Here

savage-garden-600-7
savage-garden-600-6
SAVAGE-GARDEN-LONDON-MOBILE-4

6:00 pm Registration & Welcome Reception

6:30 pm Opening Remarks & Introduction

6:35 pm Actioning the Genome Through Entrepreneurship & Start-Ups

  • Bobby Kaura Director, Illumina for Start-Ups, Global Ecosystem Development, Illumina

Synopsis

  • Open Innovation – Partnering with Pharma & Biotech
  • An overview of Illumina for Start-ups – Creating genomic VC backable companies
  • What it takes to be a backable VC company & Examples of pioneering Start-Ups

6:45 pm Developing a Chromosomal Instability Biomarker Platform for Next Generation Oncology Therapeutics

6:55 pm On the Path to Leaving No Eligible Patient Behind: Choosing the Right Diagnostic Partner to Enable Broader Patient Access to the Right Therapeutics

  • Flora Berisha Head of Dx Strategic Partnering, Oncology, Janssen, Global R&D

Synopsis

  • The importance of strategic partnerships for long-term strategic growth
  • How to identify the right strategic partner
  • Jansen’s precision medicine strategy for Oncology

7:05 pm Shaping the Future of Clinical Next Generation Sequencing Testing in Oncology

  • Megan Townsend Business Development Manager, CDx Partnerships, Illumina

Synopsis

  • Illumina’s CDx Vision: Building a single CGP/CDx solution for all market
  • The path forward to evolve testing infrastructure and gain broad patient access
  • Building strategic partnerships to evolve & grow a changing healthcare landscape

7:15 pm Interactive Panel Discussion & Q&A: Driving the Next Generation of Oncology Diagnostics & Therapeutics: We Cannot Do It Alone

  • Bobby Kaura Director, Illumina for Start-Ups, Global Ecosystem Development, Illumina
  • Jason Yip Co-Founder, Tailor Bio
  • Megan Townsend Business Development Manager, CDx Partnerships, Illumina
  • Flora Berisha Head of Dx Strategic Partnering, Oncology, Janssen, Global R&D

Synopsis

  • The latest biomarker and CDx strategies to guarantee broader patient adoption of oncology therapeutics across the globe
  • How biopharma is integrating NGS into clinical development to achieve long-term strategic stability and clinical success in oncology therapeutic development
  • How Illumina is working to bridge the different ecosystems across the cancer care continuum, from early innovation, clinical development, and patient care to drive the latest innovative concepts into marketable therapeutics and diagnostics, and to deliver future proof CDx solutions to biopharma’s oncology pipelines

7:40 pm Networking & Drinks

Synopsis

This is an informal and exclusive networking opportunity for you to engage with companies who share your goal in improving health outcomes in oncology and to identify potential routes to partner and support one another!

8:30 pm End of Illumina Engager

ABOUT ILLUMINA

illumina logo engage

At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina's innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.

www.illumina.com